Jim Simons’s Karyopharm Therapeutics KPTI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.06M | Buy |
108,214
+2,800
| +3% | +$24.3K | ﹤0.01% | 2285 |
|
|
2026
Q1 | $587K | Buy |
105,414
+45,500
| +76% | +$347K | ﹤0.01% | 2533 |
|
|
2025
Q4 | $441K | Sell |
59,914
-4,800
| -7% | -$29.4K | ﹤0.01% | 2624 |
|
|
2025
Q3 | $423K | Sell |
64,714
-1,100
| -2% | -$5.92K | ﹤0.01% | 2863 |
|
|
2025
Q2 | $284K | Buy |
65,814
+4,600
| +8% | +$22.6K | ﹤0.01% | 3061 |
|
|
2025
Q1 | $229K | Sell |
61,214
-18,959
| -24% | -$162K | ﹤0.01% | 3040 |
|
|
2024
Q4 | $813K | Sell |
80,173
-2,587
| -3% | -$31.3K | ﹤0.01% | 2601 |
|
|
2024
Q3 | $1.03M | Buy |
82,760
+32,345
| +64% | +$402K | ﹤0.01% | 2429 |
|
|
2024
Q2 | $656K | Sell |
50,415
-10,038
| -17% | -$166K | ﹤0.01% | 2554 |
|
|
2024
Q1 | $1.37M | Sell |
60,453
-70,505
| -54% | -$1.24M | ﹤0.01% | 2278 |
|
|
2023
Q4 | $1.7M | Buy |
130,958
+82,265
| +169% | +$1.11M | ﹤0.01% | 2052 |
|
|
2023
Q3 | $979K | Buy |
48,693
+4,200
| +9% | +$94.3K | ﹤0.01% | 2315 |
|
|
2023
Q2 | $1.2M | Sell |
44,493
-4,554
| -9% | -$196K | ﹤0.01% | 2361 |
|
|
2023
Q1 | $2.86M | Buy |
49,047
+36,427
| +289% | +$1.8M | ﹤0.01% | 1800 |
|
|
2022
Q4 | $644K | Sell |
12,620
-7,933
| -39% | -$550K | ﹤0.01% | 2795 |
|
|
2022
Q3 | $1.68M | Sell |
20,553
-9,767
| -32% | -$730K | ﹤0.01% | 2133 |
|
|
2022
Q2 | $2.05M | Buy |
30,320
+15,980
| +111% | +$1.47M | ﹤0.01% | 2170 |
|
|
2022
Q1 | $1.58M | Buy |
14,340
+8,613
| +150% | +$1.07M | ﹤0.01% | 2410 |
|
|
2021
Q4 | $552K | Sell |
5,727
-27,300
| -83% | -$2.72M | ﹤0.01% | 3029 |
|
|
2021
Q3 | $2.88M | Buy |
33,027
+31,796
| +2,583% | +$3.3M | ﹤0.01% | 1813 |
|
|
2021
Q2 | $191K | Buy |
+1,231
| New | +$179K | ﹤0.01% | 3256 |
|
|
2020
Q3 | – | Sell |
-12,120
| Closed | -$3.44M | – | 3531 |
|
|
2020
Q2 | $3.44M | Sell |
12,120
-23,480
| -66% | -$6.94M | ﹤0.01% | 1854 |
|
|
2020
Q1 | $10.3M | Buy |
35,600
+24,900
| +233% | +$6.87M | 0.01% | 1145 |
|
|
2019
Q4 | $3.08M | Buy |
+10,700
| New | +$2.32M | ﹤0.01% | 2112 |
|
|
2019
Q3 | – | Sell |
-4,901
| Closed | -$440K | – | 3571 |
|
|
2019
Q2 | $440K | Sell |
4,901
-56,352
| -92% | -$4.52M | ﹤0.01% | 3043 |
|
|
2019
Q1 | $5.37M | Buy |
61,253
+32,836
| +116% | +$3.64M | ﹤0.01% | 1761 |
|
|
2018
Q4 | $3.99M | Buy |
28,417
+23,704
| +503% | +$4M | ﹤0.01% | 1861 |
|
|
2018
Q3 | $1.2M | Sell |
4,713
-4,480
| -49% | -$1.24M | ﹤0.01% | 2529 |
|
|
2018
Q2 | $2.34M | Buy |
+9,193
| New | +$2.27M | ﹤0.01% | 2187 |
|
Other funds holding KPTI
ACA
Jim Simons's KPTI Position: Q2 2026 in Review
Jim Simons increased its Karyopharm Therapeutics (KPTI) stake by 2.7% in Q2 2026, buying an estimated $24.3K and bringing the position to 108,214 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2285.
Jim Simons first reported a position in KPTI in Q2 2018 and has held it in 29 quarters since. The position peaked at $10.3M in Q1 2020. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.
- Jim Simons held 108,214 shares of Karyopharm Therapeutics worth $1.06M as of Q2 2026.
- Jim Simons bought 2,800 Karyopharm Therapeutics shares in Q2 2026, an estimated $24.3K.
- Karyopharm Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2285 holding.
- Jim Simons first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 29 quarters since.
- Jim Simons's Karyopharm Therapeutics position peaked at $10.3M in Q1 2020.
- 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.